Some studies have demonstrated that EBLN3P promotes the progression of liver cancer via alteration of microRNA-144-3p/DOCK4 pathway, and osteosarcoma through modifying the miR-224-5p/Rab10 signaling axis (Li et al., 2020b; Dai et al., 2021). Here, EBLN3P is linked to liver cancer.